2356results about "Dragees" patented technology

The compositions and methods provided herein include a pharmaceutical formulation for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Also provided herein are pharmaceutical formulations for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof and one or more additional active agents. Also provided herein are methods of treating hair loss by administering to a subject in need thereof a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Further provided herein is a kit including a slow modified release vehicle comprising oral minoxidil or a pharmaceutically acceptable salt thereof.

The invention discloses an amorphous tigorasone solid dispersion which has excellent stability and dissolvability, by adding copovidone, a powerful hydrogen bond is formed between tigorasone and copovidone, and by adjusting the type of an adhesive and the proportion of the adhesive to tigorasone, the problems of easy crystal transformation of amorphous tigorasone, poor solubility and the like are solved. And the technical problem is solved. The tigorazan tablet prepared from the amorphous solid dispersion provided by the invention does not generate crystal transformation after being placed for 30 days under the conditions of 60 DEG C and 75% RH, and the dissolution curve in a standard medium is consistent with that of a reference preparation.

The invention provides a solid oral dosage form comprising tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.

The present invention relates to a stable pharmaceutical composition of therapeutically active agent, wherein the amount of nitrosamine impurity is below the FDA acceptable intake limit for shelf life of the pharmaceutical composition and a process for preparing the same.

The invention provides a melogabalin besylate tablet and a preparation method thereof, the melogabalin besylate tablet comprises a plain tablet and a coating, the plain tablet comprises, by mass, 4.39% of melogabalin besylate, 75-85% of mannitol 150SD, 3-10% of a disintegrating agent, 0.5-3% of a lubricant, 0.1-0.5% of an adsorbent, 1-10% of a filler, 0.5-3% of an antioxidant A and 0.1-3% of an antioxidant B; and the coating comprises the following components in percentage by mass: 30-45% of talcum powder, 2-10% of lauryl sodium sulfate, 30-45% of glycerol monocaprylate / dicaprylate, 2-10% of titanium dioxide, 30-45% of polyvinyl alcohol, 0.5-2% of iron oxide yellow and 0.5-2% of iron oxide red. The melogabalin besylate tablet prepared by the invention uses specific coating composition and specific coating parameters, so that the melogabalin besylate tablet can be stably stored without a drying agent and a composite aluminum bag for medicine packaging, the stability of the tablet is greatly improved, the complexity of equipment required by production is simplified, and the production cost is greatly saved.

The invention discloses a method for preparing a tigorazan tablet by a fluidized bed granulation method. The method comprises the following steps: 1) preparing a pharmaceutical active component tigorazan and an adhesive into a granulation solution, and granulating the granulation solution and a filler in a fluidized bed to obtain granules; the invention relates to a preparation method of a tigorazan tablet, which comprises the following steps: 1) preparing granules, 2) carrying out dry granulation on the granules, and 3) tabletting the granules obtained after dry granulation in the step 2) and optional pharmaceutically acceptable auxiliary materials so as to obtain the tigorazan tablet. The tablet prepared by a fluidized bed preparation method can solve the problem of easy crystal transformation of amorphous raw materials, and is simple and convenient in process, good in stability and more suitable for commercialized mass production.

Disclosed herein is a tablet composition comprising 3-[(1S,2S)-1-[5-[(4S)-2,2-dimethyloxolan-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-1-yl]-2-methylcyclopropyl]-4H-1,2,4-oxadiazol-5-one, or a pharmaceutically acceptable salt thereof, and a pH adjuster. In one embodiment, the tablet composition comprises a spray-dried dispersion (SDD) of 3-[(1S,2S)-1-[5-[(4S)-2,2-dimethyloxolan-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-1-yl]-2-methylcyclopropyl]-4H-1,2,4-oxadiazol-5-one, or a pharmaceutically acceptable salt thereof, and the SDD also comprises a polymer for maintaining the amorphous state.

Stable and bioavailable formulations and dosage forms comprising a dispersion (e.g., spray-dried dispersion) of solid amorphous 6-(cyclopropancamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide (Formula (I): BMS-986165) in a solid polymer matrix are provided for the treatment of auto-immune and auto-inflammatory diseases such as an inflammatory bowel disease (IBD) and psoriasis.

The invention relates to the technical field of medicines, in particular to a sustained-release coating as well as a preparation method and application thereof. The coating adopts a three-layer gradient structure design and comprises an inner layer coating, a middle layer coating and an outer layer coating, and the layers are compounded and matched through ethyl cellulose and hydroxypropyl methylcellulose with different molecular weights and are combined with talcum powder filling amount with gradient decreasing and a triethyl citrate plasticizer, so that accurate regulation and control of drug release are realized. Through hierarchical swelling-diffusion dynamic balance, burst release is inhibited, the inner layer has high talcum powder content to resist initial swelling stress, the outer layer has low filling amount to maintain hydrophobic continuity, interface defects are reduced in combination with high-temperature curing, and the release stability and long-term storage performance of drugs such as dihydroergoline mesylate are remarkably improved; the problems of sudden release, damp-heat sensitivity, impurity generation and the like of a traditional single-layer coating are solved.

The invention discloses an abesilil raw material medicine, a composition, a tablet and a preparation method thereof. The particle size distribution of the abesilil raw material medicine is as follows: D10 is more than or equal to 20 microns, D90 is more than or equal to 60 microns and less than or equal to 300 microns, and the span (D90-D10) / D50 is less than or equal to 2.5. According to the present invention, the large raw material particle size within a certain range is provided, the dissolution rate and the dissolution amount of the abelsilil tablet in the pH 6.8 medium can be easily improved, the sticking phenomenon during the tabletting process can be solved, the production process is simple, the production period is short, the production cost is low, the mixing and the tabletting are smooth, and the dissolution end point is high.

The invention relates to the technical field of pharmaceutical preparations, and discloses a saxagliptin tablet containing a coating layer and a preparation process of the saxagliptin tablet. Comprising the following operation steps: (1) uniformly mixing saxagliptin, a diluent, a disintegrating agent and a lubricant, performing dry granulation, and tabletting to obtain a tablet core; (2) adding hydroxypropyl methyl cellulose phthalate, eudragit and diethyl phthalate into absolute ethyl alcohol, and uniformly mixing to obtain an enteric coating solution; (3) adding modified chitosan and hydroxypropyl methyl cellulose into absolute ethyl alcohol, and uniformly mixing to obtain a gastric-soluble coating solution; step 2: (1) spraying an enteric coating solution on the surface of the tablet core, and drying to form an enteric coating layer; and (2) spraying a gastric-soluble coating solution on the enteric coating layer, and drying to form a gastric-soluble coating layer, thereby obtaining the saxagliptin tablet.

Disclosed herein are compounds, compositions, and methods for promoting neuronal growth and / or improving neuronal structure with the compounds and compositions disclosed herein. Also described are methods of treating diseases or disorders that are mediated by the loss of synaptic connectivity and / or plasticity, such as neurological diseases and disorders, with non-hallucinogenic psychoplastogens.

The invention provides an extraction method of hirudin, an oral preparation containing the hirudin and a preparation method of the oral preparation, and belongs to the technical field of leech processing and traditional Chinese medicine. The hirudin extraction method comprises the following steps: S1, soaking fresh leeches in a freeze-drying protective agent, taking out the leeches, wiping the surfaces of the leeches, pre-freezing the leeches at the temperature of 40 DEG C below zero to 50 DEG C below zero for 1-2 hours, and freeze-drying the leeches at the temperature of 20 DEG C below zero to 30 DEG C below zero for 4-6 hours to obtain freeze-dried leeches; s2, crushing the freeze-dried leeches, adding the crushed leeches into water, adding enzyme and lecithin, performing enzymolysis for 4-6 hours under the conditions that the temperature is 35-40 DEG C and the pH value is 7.5-8.5, and cooling to room temperature to obtain an enzymolysis product; s3, sterilization, ultrafiltration and drying are conducted, and hirudin is obtained. The hirudin extracted by the method is high in activity and high in recovery rate.

The invention relates to a pharmaceutical composition comprising benzgalantamine and uses and methods for the preparation thereof. The present invention provides a pharmaceutical composition in the form of a tablet, said tablet comprising a tablet core, wherein said core comprises benzgalantamine (ALPHA-1062) or salt thereof, and an enteric coating, wherein said enteric coating is configured for dissolution at pH 5.5 and above. The pharmaceutical composition could be used in the treatment of a brain disease associated with cognitive impairment and / or with a cholinergic deficit. The invention further provides a method for preparing the pharmaceutical composition.

Compositions including dihydromyricetin (DHM) and methods for forming them through hot melt extrusion.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a melogabalin besylate tablet containing a stabilizer and a preparation method of the melogabalin besylate tablet. The melogaba besylate tablet containing the stabilizer comprises a coating and a tablet core, wherein the tablet core comprises the following components: melogaba besylate, the stabilizer, a disintegrating agent, a lubricating agent and the balance of a filling agent; and the coating is prepared from the following materials: an Intai W100 film coating premixing agent and acrylic resin IV. The filling agent comprises xylitol, pregelatinized starch and maltodextrin in a mass ratio of (3-4): 3: (1-2). The stabilizer is vitamin E succinic acid polyethylene glycol ester. The coating is prepared from the following materials: an Intai W100 film coating premixing agent and acrylic resin IV in a mass ratio of (1-1): (1-2). According to the melogabalin besylate tablet prepared by the invention, the stability and the dissolution performance can be synchronously improved.

The invention discloses melogabalin besylate tablets and a preparation method thereof, a tablet core comprises melogabalin besylate, a filler, a disintegrating agent, a lubricant, a flow aid and a stabilizer, the disintegrating agent is sodium carboxymethyl starch, and the stabilizer is tocopherol and tartaric acid; on the basis of selecting sodium carboxymethyl starch as a disintegrating agent, the melogabalin besylate tablet of which the stability (especially the quality control of impurities I) is superior to that of a reference preparation is prepared by investigating the variety and the dosage of a stabilizing agent and selecting a specific stabilizing agent combination; the technical prejudice that the stability of calcium carboxymethyl cellulose is superior to that of sodium carboxymethyl starch in the prior art is overcome.

The invention relates to the field of pharmacy, and discloses a felodipine sustained release tablet and a preparation method thereof.The felodipine sustained release tablet comprises a tablet core and a film coating layer wrapped outside the tablet core, and the tablet core comprises the following components in parts by mass: 3.5-5.0 parts of felodipine nanocrystals; 50 to 65 parts of modified hydroxypropyl methylcellulose; the preparation method comprises the following steps: S1, preparing felodipine nanocrystals: dissolving felodipine in an organic solvent, and carrying out anti-solvent precipitation and high-pressure homogenization treatment, so as to obtain a nanocrystal suspension; drug nanocrystals are embedded between silicate layers through an ultrasonic embedding technology, and burst release is inhibited by combining physical confinement and electrostatic adsorption; the gradient pore skeleton constructs a pore layer-by-layer decreasing structure through fluidized bed multi-temperature zone deposition, the release rate is accurately regulated and controlled, and collapse is avoided; the ionic liquid stabilizer is introduced, and the problems of nanocrystal aggregation and degradation are synchronously solved through hydrogen bond anchoring and an antioxidant function.

Methods for treating immune thrombocytopenia comprising administering at least one compound chosen from (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile (rilzabrutinib) and pharmaceutically acceptable salts thereof are disclosed.

There is provided an alkali metal salt of 4-chloro-N-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide and formulations thereof. This salt finds particular utility in the treatment or prevention of a disorder or condition ameliorated by the activation of AMPK.

The present disclosure is directed to oral tablet of ribociclib including its salt(s). One embodiment of the present disclosure is directed to tablet of ribociclib with high drug load with an immediate release profile. One embodiment of the present disclosure is directed to coated tablet of ribociclib. Another embodiment of the present disclosure is directed to coated tablet of ribociclib where the coating is an aqueous moisture barrier coating (e.g., Opadry® amb II coating where the coating is PVA based).

The present disclosure relates to a stable pharmaceutical composition comprising a fixed dose combination of olbistetrapib and ezetimibe or a salt, solvate, or derivative of olbistetrapib and ezetimibe. The disclosure further describes the use of ezetimibe and Eubiquitrapib, for example in such fixed dose combinations, for the preparation of an agent for the treatment of a subject in need of lowering LDL-cholesterol or a subject suffering from hyperlipidemia or mixed dyslipidemia, and methods of treatment for the subject.

The present disclosure provides pharmaceutic compositions for oral delivery comprising an antisense oligonucleotide (e.g., CIVI 008) and an oral delivery agent such as 5-CNAC. In some aspects, the disclosure provides a capsule comprising a dry blend of CIVI 008 and 5-CNAC, and optionally a statin.

Modified release formulations, such as solid oral dosage forms comprising a core composition comprising Compound (I) and / or a pharmaceutically acceptable salt thereof; a sub-coating layer coating the core composition, said sub-coating layer comprising a polyvinyl alcohol and / or a hydroxypropyl methyl cellulose; and an enteric coating layer encapsulating the sub-coating layer and the core composition, said enteric coating layer comprising at least one polymer selected from an acrylic / methacrylic / ethacrylic acid homopolymer and copolymers thereof, a cellulose derivative, and a polyvinylpyrrolidone, and methods of administration of a Bruton's tyrosine kinase (BTK) inhibitor using said formulations.

The invention relates to a pharmaceutical composition in the form of a tablet, said tablet comprising a tablet core, wherein said core comprises benzgalantamine (ALPHA-1062) or salt thereof, and an enteric coating, wherein said enteric coating is configured for dissolution at pH 5.5 and above. Further the invention relates to the pharmaceutical composition for use in the treatment of a brain disease associated with cognitive impairment and / or with a cholinergic deficit. The invention further relates to a method for preparing the pharmaceutical composition.

An implantable device for delivery of a macromolecular drug compound is provided. The device comprises a core having an outer surface and a membrane layer positioned adjacent to the outer surface of the core. The core comprises a core polymer matrix within which is dispersed a drug compound having a molecular weight of about 5 kDa or more, the polymer matrix containing a hydrophobic polymer. The membrane polymer matrix includes from about 70 wt. % to about 99 wt. % of an ethylene vinyl acetate copolymer.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a pharmaceutical composition containing irbesartan and amlodipine and a preparation method of the pharmaceutical composition. The pharmaceutical composition comprises an irbesartan layer, an amlodipine besylate layer and a coating layer, the irbesartan layer is prepared from the following raw materials: irbesartan, croscarmellose sodium and hydroxypropyl cellulose; the amlodipine besylate layer is prepared from the following raw materials: amlodipine besylate, croscarmellose sodium and hydroxypropyl cellulose; the model number of the hydroxypropyl cellulose is HPC-M. According to the invention, irbesartan and proper auxiliary materials are subjected to wet granulation, so that the problems of low bulk density and poor fluidity of irbesartan are solved. The amlodipine p-besylate and suitable auxiliary materials are subjected to fluidized bed granulation, so that the problems of poor mixing uniformity and low content are solved, the stability of the product is improved, and the amlodipine p-besylate has a good application prospect.

The present invention relates to polypeptide and peptide vaccine compositions and methods that reduce methane and / or hydrogen production in animals. The present invention also relates to the treatment of diseases that are associated with methanogens.

The invention discloses a sustained-release pill as well as a preparation method and application thereof, and belongs to the technical field of medicines. The sustained-release pill comprises a pill core and a coating layer coated outside the pill core, the pellet core is prepared from the following raw materials in parts by mass: 8 to 14 parts of loxoprofen sodium, 30 to 60 parts of a filling agent, 3 to 10 parts of an adhesive, 2 to 10 parts of a disintegrating agent, 0.1 to 2 parts of a penetration enhancer, 0.05 to 0.2 part of a pH regulator, 0.1 to 0.5 part of a surfactant and 0 to 20 parts of an auxiliary agent; the coating layer is prepared from an aqueous dispersion liquid containing acrylic resin; the coating layer is prepared from an aqueous dispersion liquid containing acrylic resin. Aiming at the drug characteristics of loxoprofen sodium, the loxoprofen sodium sustained-release tablet is composed of specific auxiliary materials, the drug composition is optimized, the drug release rate is accurately controlled, the bioavailability and stability of the drug are effectively improved, and the loxoprofen sodium sustained-release tablet has a good application prospect in preparation of antipyretic and analgesic drugs.